New hope for deadly parasitic disease as experimental drug enters testing
Disease control
Ongoing
This study is testing a new oral drug called LXE408 for treating visceral leishmaniasis, a serious parasitic infection. It will compare two different dosing schedules of LXE408 against the current standard treatment (AmBisome) in about 101 patients aged 12 and older. The main goa…
Phase: PHASE2 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC